HomeHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Nakaraang pagsara
€25.85
Sakop ng araw
€25.67 - €25.67
Sakop ng taon
€19.52 - €36.69
Market cap
3.58B USD
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(USD) | Mar 2024info | Y/Y na pagbabago |
---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 126.19M | 28.63% |
Net na kita | -125.30M | -357.42% |
Net profit margin | — | — |
Kita sa bawat share | -1.02 | -326.67% |
EBITDA | -121.67M | -339.34% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(USD) | Mar 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 520.91M | 8.30% |
Kabuuang asset | 955.15M | 7.16% |
Kabuuang sagutin | 459.74M | 7.87% |
Kabuuang equity | 495.40M | — |
Natitirang share | 124.20M | — |
Presyo para makapag-book | 6.63 | — |
Return on assets | -39.90% | — |
Return on capital | -43.18% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | -125.30M | -357.42% |
Cash mula sa mga operasyon | -92.38M | -191.68% |
Cash mula sa pag-invest | -268.94M | -645.70% |
Cash mula sa financing | 430.78M | 82,741.73% |
Net change in cash | 69.49M | 203.27% |
Malayang cash flow | -91.82M | -262.49% |
Tungkol
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Itinatag
Ene 1, 2004
Headquarters
Website
Mga Empleyado
525